title: Etoricoxib for pain management during thyroid surgery--a prospective, placebo-controlled study.
abstract: OBJECTIVE
  To assess the efficacy of etoricoxib in pain treatment during thyroid surgery.
  
  
  METHODS
  Double-blind, placebo-controlled, randomized trial.
  
  
  METHODS
  A secondary-level central hospital in Finland.
  
  
  METHODS
  Sixty-nine consecutive patients (59 women) aged 18 to 70 years who underwent thyroid surgery.
  
  
  METHODS
  Patients were randomized to receive etoricoxib 120 mg (n = 34) or placebo (n = 35) by mouth 60 minutes before surgery. After surgery oxycodone 2 mg administered intravenously was provided for rescue analgesia.
  
  
  METHODS
  Oxycodone consumption during the first 6 (primary) and the 7 to 24 hours (secondary) after surgery.
  
  
  RESULTS
  During the first 6 hours, all patients in the placebo group and 31 of 34 patients in the etoricoxib group were given oxycodone for rescue analgesia (P = 0.072). In the 7 to 24 postsurgical hours, 25 of 35 patients in the placebo group versus 16 of 34 patients in the etoricoxib group needed rescue analgesics (mean difference 24%, 95% CI -1 to 47%, P = 0.039).
  
  
  CONCLUSIONS
  Etoricoxib 120 mg reduced pain in the 7 to 24 postsurgical time period but did not have opioid-sparing effect during the first 6 hours after surgery.
authors.affiliation: Department of Otorhinolaryngology, Kuopio University Hospital, Kuopio, Finland.
authors.forename: Grigori
authors.initials: G
authors.lastname: Smirnov
authors.forename: Markku
authors.initials: M
authors.lastname: Terävä
authors.forename: Henri
authors.initials: H
authors.lastname: Tuomilehto
authors.forename: Kimmo
authors.initials: K
authors.lastname: Hujala
authors.forename: Marjatta
authors.initials: M
authors.lastname: Seppänen
authors.forename: Hannu
authors.initials: H
authors.lastname: Kokki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000698:Analgesia / Q000379:methods*; D000701:Analgesics, Opioid / Q000008:administration & dosage; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D000077613:Etoricoxib; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010098:Oxycodone / Q000008:administration & dosage; D010149:Postoperative Pain / Q000517:prevention & control*; D011446:Prospective Studies; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*; D013959:Thyroid Diseases / Q000601:surgery; D013965:Thyroidectomy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D016861:Cyclooxygenase Inhibitors; D011725:Pyridines; D013450:Sulfones; D010098:Oxycodone; D000077613:Etoricoxib